@article {24664,
	title = {Etoposid-based therapy for severe forms of COVID-19},
	journal = {Medical Hypotheses},
	volume = {PRE PROOF},
	year = {2020},
	abstract = {AbstractThe new coronavirus infection COVID-19 has quickly become a global health emergency.Mortality is principally due to severe Acute Respiratory Distress Syndrome (ARDS) whichrelays only on supportive treatment. Numerous pathological, clinical and laboratory findingsrise the similarity between moderate to severe COVID-19 and haemophagocyticlymphohistiocytosis (HLH). Etoposide-based protocol including dexametasone is the standardof care for secondary HLH. The protocol has been successfully used in HLHs that are secondaryto EBV and H1N1 infections by inducing complete response and pronged survival. Theseobservations prompt to consider this cytotoxic therapy in HLH associated to moderately severeto severe forms of COVID-19.Key words: COVID-19; Haemophagocytic lymphohistiocytosis; HLH; Etoposide},
	url = {https://doi.org/10.1016/j.mehy.2020.109826},
	author = {Kamel HAMIZI1,2, Souhila AOUIDANE3, Ghania BELAALOUI1}
}
